Objectives To develop evidence-based European League Against Rheumatism (EULAR)
recommendations for vaccination in patients with autoimmune inflammatory rheumatic …

… Most transplant recipients were children (n = 25), received a myeloablative busulphan-based
regimen (n = 23), and had unmodified marrow allografts (n = 23) from human leukocyte …

… Nico M Wulffraat2, … . The clinical continuum of cryopyrinopathies: novel CIAS1 mutations
in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273–85. doi:…

We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1,
also known as γ chain (γc) deficiency] in 9 out of 10 patients by retrovirus-mediated γc …

To the Editor: We recently reported (April 18 issue) 1 the sustained correction of X-linked
severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc …

Background X-linked severe combined immunodeficiency due to a mutation in the gene
encoding the common γ (γc) chain is a lethal condition that can be cured by allogeneic stem-cell …

… disease onset between patients classified by the 28-member expert panel as having
macrophage activation syndrome (MAS) (n 5 95) and those classified as not having MAS (n 5 296) …

Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We …

… For the degranulation assay, we cultured the cells in the same conditions using unlabelled
targets and measured the release of N-α-benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT) …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…